Demecal
Demecal Europe B.V. has developed a patented technology for the analysis of blood. It shares the patents with Leisure Incorporated, a Japanese company. Demecal owns the rights exclusively to Europe and jointly to the USA, whilst Leisure owns the rights to Asia.
Demecal's equipment, known as 'The Demecal Lifestyle Test', enables on-the-spot plasma production using only one drop of blood. This plasma is sent to the ISO certified laboratory and analysed according to hospital standards. A validation study was presented by Demecal at the congress for Pre Diabetes in Barcelona last April and during the Euromedlab congress in Amsterdam in June this year, showing that the Demecal method is as reliable, on ten different parameters including HIV and other STD's, liverfunction and PSA (prostate) will be added.
There are multiple benefits to the Demecal tests. Patients will no longer be required to provide large amounts of blood - often an unpleasant and time consuming process. Doctors will have the advantage of an additional revenue stream as they themselves will be able to perform the procedure rapidly, during the consultation, whilst insurance companies will have significantly reduced reimbursement costs from the blood analysis process. There are further vast opportunities for example through internet sales, whereby consumers will be able to order a test in the mail, perform it themselves and mail it to the laboratory for interpretation. Pharmaceutical companies whishing to obtain large-scale blood samples will be able to do so more easily.
Of the four main target areas of hospitals/service laboratories, retail, health insurance companies and internet sales, Demecal is currently focusing the bulk of its efforts on hospitals/service laboratories and internet sales. The first contracts have already been signed and Demecal has started the first pilot projects.
The complete blood testing market in Europe alone is currently estimated at 3.8 billion laboratory tests and 3.9 billion self tests per year. Both are projected to grow at a rate of 5% per year. The directors of MeDaVinci see no logical reason for the medical industry to continue to employ the existing methods of blood analysis for the majority of these annual tests.
You can also visit the website www.demecal.nl